|‘Ahead of its peers in clinical development’: Fan on Fate Therapeutics
Martin Fan, Vice President of Equity Research at Wedbush, discussed Fate Therapeutics as one of his top picks in the biotech sector. He highlighted the company's advanced position in clinical development compared to its competitors. This interview took place on BNN Bloomberg, where Fan shared his insights on promising biotech investments.
Form 424B5 Fate Therapeutics Inc For: 13 November By Investing.com
This article announces the filing of Form 424B5 by Fate Therapeutics Inc. on November 13. The brief notice highlights the immediate availability of this SEC filing, which is a prospectus for shelf registration. It also notes Fate Therapeutics Inc.'s stock performance with a -16.51% change.
With $139.1M in cash, cash equivalents and short-term investments, Fate Therapeutics (FATE) may sell stock.
Fate Therapeutics Inc. (FATE) has filed a prospectus supplement to offer and sell up to $100 million in common stock through an at-the-market offering with Leerink Partners LLC. The company plans to use the net proceeds for working capital and general corporate purposes, including research and development and clinical trials. As of September 30, 2026, Fate Therapeutics reported $139.1 million in cash, cash equivalents, and short-term investments.
Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
Fate Therapeutics presented updated clinical data for FT819 and preclinical data for FT839 at ACR Convergence 2026, demonstrating favorable safety and encouraging clinical activity in lupus patients without conditioning chemotherapy. The data highlight meaningful responses, including DORIS remission and LLDAS, and supports the advancement of their off-the-shelf CAR T-cell programs for autoimmune diseases. Patient perspectives also showed a strong preference for immediate access, shorter hospital stays, and lighter conditioning regimens, aligning with Fate Therapeutics' development strategy.
Fate Therapeutics Presents New FT819 Data at ACR
Fate Therapeutics presented updated clinical data for FT819 and preclinical data for FT839 at the American College of Rheumatology (ACR) Convergence 2026. The data highlighted favorable safety and encouraging clinical responses in lupus patients treated with FT819, even without conditioning chemotherapy. Additionally, new preclinical data for FT839 showed its ability to eliminate activated immune cells in models of rheumatoid arthritis, supporting its potential for treating complex autoimmune diseases without the need for conditioning chemotherapy.
Form 13D/A FATE THERAPEUTICS INC For: 9 November By Investing.com
This article from Investing.com announces the filing of a Form 13D/A for FATE THERAPEUTICS INC, pertaining to activity on November 9, 2026. Form 13D/A is an amendment to a Schedule 13D, which is filed with the SEC when a person or group acquires beneficial ownership of more than 5% of a company's voting stock. The document likely provides updated information regarding their holdings or intentions.
A fund crossed 5% of Fate Therapeutics (FATE) without trading since the prior amendment.
Redmile Capital Offshore II Master Fund, Ltd. has become a reporting person for Fate Therapeutics (FATE) after its beneficial ownership surpassed 5% due to a change in FATE's outstanding share count, not from new transactions. The fund now reports beneficial ownership of 6,426,298 shares, or 5.03%. Other Redmile entities and Jeremy C. Green also report significant stakes.
Form 144 FATE THERAPEUTICS INC For: 7 November By Investing.com
This article reports on the filing of Form 144 for Fate Therapeutics Inc. on November 7. The filing is briefly mentioned as a stock market update by Investing.com. The content of the Form 144 is not detailed in the article.
Form 144 FATE THERAPEUTICS INC For: 7 November By Investing.com
This article reports on a Form 144 filing by FATE THERAPEUTICS INC for November 7. Form 144 is a notice of the intent to sell restricted securities. The article provides the publication details of this financial market news.
Fate Therapeutics (NASDAQ:FATE) Given New $3.00 Price Target at Wells Fargo & Company
Wells Fargo & Company has lowered its price target for Fate Therapeutics (NASDAQ:FATE) to $3.00 from $3.50, while maintaining an "equal weight" rating, suggesting a potential upside of 55.84%. Despite this, analyst sentiment leans positive with a "Moderate Buy" consensus and an average price target of $5.80 from other firms. Fate Therapeutics recently reported better-than-expected quarterly earnings, with a loss of $0.25 per share and revenue of $1.35 million.
Form 424B5 Fate Therapeutics Inc For: 6 November By Investing.com
This article reports on the filing of Form 424B5 by Fate Therapeutics Inc. on November 6, 2026. The filing is an SEC document, which typically relates to a prospectus or prospectus supplement for securities offerings. The brief mention indicates an official disclosure from the company.
After $8M in prior stock sales, Fate Therapeutics (FATE) taps Leerink for a new offering.
Fate Therapeutics (FATE) plans to offer and sell up to $100 million in common stock through an "at-the-market" offering via Leerink Partners, replacing a prior agreement with Jefferies LLC under which it sold $8 million in shares. The proceeds are intended for working capital and general corporate purposes, including research and development and clinical trials. As of September 30, 2026, Fate Therapeutics reported $139.1 million in cash, cash equivalents, and short-term investments.
Fate Therapeutics (FATE) files $300M mixed shelf
Fate Therapeutics (NASDAQ: FATE) has filed a $300 million mixed shelf offering, which includes common stock, preferred stock, debt securities, warrants, and units. This type of filing allows the company to issue various securities over time. The stock price was reported at $1.85, showing an 11.48% decrease, with an overall analyst rating of "SELL."
Fate Therapeutics earnings beat by $0.02, revenue topped estimates
Fate Therapeutics (NASDAQ: FATE) announced its third-quarter earnings, reporting an EPS of $-0.250, which surpassed analyst estimates by $0.02. The company also exceeded revenue expectations, bringing in $1.35M against a consensus estimate of $1.17M. Despite a recent -25.360% drop in stock price over the last three months, the company has seen an 83.170% increase over the past year.
Fate Therapeutics Q3FY26 Results: Net loss narrows 5% YoY to $30.7 million
Fate Therapeutics reported a net loss of $30.7 million for Q3FY26, a 5% narrowing year-over-year, driven by a 12% decline in total operating expenses. The company extended its cash runway to mid-2028 with a $15.0 million grant and highlighted positive Phase 1 data for its FT819 CAR T-cell therapy in autoimmune patients, showing a 100% renal response rate in a selected cohort.
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Fate Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting significant progress in its clinical development programs for autoimmune diseases and cancer. The company announced favorable safety and efficacy data for FT819 in lupus nephritis, the initiation of the Phase 1/2 COMPLETE trial for FT839, and a $15.0 million CIRM grant to support its RECLAIM-LN trial. Fate Therapeutics also extended its cash runway to mid-2028 with $139.1 million in cash, cash equivalents, and investments.
Fate Therapeutics Reports Q3 2026 Results, $139.1 Million in Cash
Fate Therapeutics reported a Q3 2026 net loss of $30.7 million and collaboration revenue of $0.0 million. The company ended the quarter with $139.1 million in cash, cash equivalents, and investments, expecting its cash runway to extend to mid-2028. Additionally, Fate Therapeutics provided updates on the progress of its FT819 and FT839 autoimmune programs, including the launch of a new Phase 1/2 basket trial for FT839.
Fate Therapeutics stock: New hires receive 300,000 options
Fate Therapeutics recently awarded stock options and restricted stock units to new non-executive employees, including 300,000 options at an exercise price of $2.01 per share and 87,000 restricted stock units. These equity awards, approved under the company's inducement equity plan, are subject to four-year vesting schedules, contingent on continued employment. The biopharmaceutical company, headquartered in San Diego, specializes in developing programmed cellular immunotherapies for cancer and immune disorders.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE) announced new employee inducement awards on November 2, 2026, granting 300,000 non-qualified stock options at $2.01 per share to one non-executive employee and 87,000 restricted stock units to two non-executive employees. These awards, approved by the Compensation Committee, vest over four years subject to continuous employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants aim to incentivize newly hired personnel to join the company.
A proposed sale of 6,582 Fate Therapeutics (FATE) shares includes funds to cover equity-award taxes.
Fate Therapeutics officer Kamal M. Adawi has proposed the sale of 6,582 common shares, valued at $13,524.69, to cover tax obligations from a vested equity award. The shares are linked to restricted stock vesting that occurred on November 2, 2026, with the proposed sale date listed as November 3, 2026. This transaction was filed as a Form 144 with the SEC.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new employee inducement awards under Nasdaq Listing Rule 5635(c)(4). These awards include non-qualified stock options for 300,000 shares to one new non-executive employee and restricted stock units (RSUs) for 87,000 shares to two new non-executive employees. The grants, approved by the Compensation Committee, are an inducement for their employment, with vesting periods of four years for both options and RSUs.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new inducement awards to newly-hired non-executive employees on November 2, 2026. These awards include non-qualified stock options for 300,000 shares and restricted stock units (RSUs) for 87,000 shares, approved by the Compensation Committee. The grants were made under the Company’s Amended and Restated Inducement Equity Plan, aligning with Nasdaq Listing Rule 5635(c)(4).
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new inducement awards to recently hired non-executive employees in accordance with Nasdaq Listing Rule 5635(c)(4). These awards include non-qualified stock options to purchase 300,000 shares for one employee and restricted stock units (RSUs) representing 87,000 shares for two employees. The grants were approved by the Compensation Committee and are subject to four-year vesting schedules contingent on continuous employment.
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Average Target Price of $5.90 According to Analysts
Fate Therapeutics (NASDAQ:FATE) has received an average "Hold" rating from analysts, with a 12-month average target price of $5.90. The company reported a quarterly loss of $0.25 per share and $2.08 million in revenue, remaining unprofitable with a negative net margin. Institutional investors hold a significant 97.54% stake, including recent purchases by BlackRock and Johnson & Johnson.
Fate Therapeutics Q3 2026 Earnings Date and Estimates
Fate Therapeutics (NASDAQ:FATE) is estimated to report its Q3 2026 earnings on Thursday, November 12, 2026, before market open, with a conference call scheduled for November 13, 2026, at 9:30 AM ET. Analysts expect the company to report earnings of -$0.2701 per share on revenue of $1.14 million, representing a significant decline from the prior year's revenue of $1.74 million. The company has a strong track record, beating consensus EPS estimates in 7 of its last 8 quarters.
Fate Therapeutics, Inc. (FATE) Seasonal returns chart
This article presents the seasonal returns chart for Fate Therapeutics, Inc. (FATE), showing the average monthly price return from 2016 to 2026. It also includes current stock information for FATE, such as its real-time price and overnight trading activity. The data aims to help investors understand the stock's historical seasonality.
Fate Therapeutics, Inc. (FATE) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Fate Therapeutics, Inc. (FATE), showing average monthly price returns from 2016 to 2026. It also displays real-time stock information, including the closing price and overnight trading activity. The page appears to be a financial data presentation from Yahoo Finance.
Fate Therapeutics, Inc. (F6T.F) Seasonal returns chart
This article provides a seasonality chart for Fate Therapeutics, Inc. (F6T.F), displaying the average monthly price return between 2016 and 2026. The stock was trading at 1.8180 EUR, down 0.76% at the close on November 2nd.
FATE Q3'26 Earnings: EPS estimate is (0.27) USD
Fate Therapeutics, Inc. (FATE) is projected to release its Q3'26 financial results on October 29. Analysts estimate revenue for the quarter to be $1.14 million and earnings per share (EPS) at ($0.27) USD. The article includes a table detailing past revenue and EPS figures, along with estimates and surprise percentages.
Allo and goodbye: Artiva NK cell therapy meets Fate in RA
Artiva Biotherapeutics Inc. (NASDAQ:ARTV) saw its shares drop significantly after its allogeneic natural killer (NK) cell therapy candidate, AlloNK (AB-101), encountered serious mid-stage issues. This setback redirected investor attention to competitors like Nkarta Inc. and Fate Therapeutics Inc. The article reports on the stock's 30.7% decline on October 27, 2026, following the news.
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)
Wedbush has reaffirmed its "Outperform" rating for Fate Therapeutics (NASDAQ:FATE) and maintained a $7.00 price target, suggesting a potential upside of 238.16% from the current stock price. Analyst sentiment for FATE is mixed, with an average "Hold" rating and a $5.90 target price, based on four Buy, two Hold, and one Sell recommendation. The biopharmaceutical company recently reported a quarterly loss of $0.25 per share, aligning with estimates, and revenue of $2.08 million, while institutional investors hold 97.54% of the company's stock.
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Fate Therapeutics (NASDAQ: FATE) presented updated preliminary Phase 1 clinical data for its FT819 product candidate in patients with active lupus nephritis (LN) at the American Society of Nephrology Kidney Week 2026. The data, as of an August 18, 2026 cutoff, showed a 100% renal response at Month 6 in patients treated with FT819 and bendamustine conditioning, alongside an encouraging safety profile with no dose-limiting toxicities. These results reinforce the value of the ongoing Phase 2 RECLAIM-LN study and highlight FT819's potential as an on-demand, off-the-shelf CAR T-cell therapy for refractory, moderate-to-severe SLE with LN.
Fate Therapeutics Reports FT819 Lupus Kidney Responses
Fate Therapeutics announced preliminary Phase 1 results for FT819 in lupus nephritis, showing renal responses in two evaluable patients. Both patients achieved complete or primary efficacy renal responses at Month 6, with one response persisting through Month 24, and an approximately 50% mean reduction in urine protein-to-creatinine ratio. The company is advancing FT819 into its Phase 2 RECLAIM-LN study, with no dose-limiting toxicities reported across 29 patients in autoimmune disease studies.
Two people with lupus kidney disease saw urine protein fall about 50% on average after Fate's cell therapy.
Fate Therapeutics (FATE) presented updated preliminary Phase 1 data for its FT819 cell therapy in lupus nephritis, showing promising renal responses and a favorable safety profile. Two evaluable patients treated with FT819 and bendamustine conditioning achieved complete or primary efficacy renal responses at Month 6, with an approximately 50% mean reduction in urine protein. The company highlighted that the therapy allowed for discontinuation of immunosuppressants and showed significant improvements in lupus disease activity and fatigue, supporting the ongoing Phase 2 RECLAIM-LN study.
Fate Therapeutics shares Phase 1 FT819 data for lupus nephritis
Fate Therapeutics presented updated Phase 1 clinical data for its CAR T-cell candidate FT819 in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN) at Kidney Week 2026. The data showed promising renal responses, with evaluable patients achieving complete or primary efficacy renal responses and significant reductions in urine protein-to-creatinine ratio. The treatment also demonstrated a favorable safety profile and clinically meaningful reductions in lupus disease activity scores.
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Fate Therapeutics (NASDAQ: FATE) announced updated Phase 1 clinical data for FT819, an anti-CD19 CAR T-cell therapy, in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN). The data, presented at ASN Kidney Week 2026, showed a 100% renal response at Month 6 in active LN patients treated with FT819 and bendamustine, with an encouraging safety profile. These findings reinforce the value of the ongoing Phase 2 RECLAIM-LN study and highlight FT819's potential as an off-the-shelf, on-demand CAR T-cell therapy for broader patient access.
Fate Therapeutics, Inc. Estimates – NASDAQ:FATE
This page provides financial estimates for Fate Therapeutics, Inc. (NASDAQ: FATE), allowing users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. It highlights the ability to compare actual results with average, high, and low estimates, and visualize trends over time for informed investment decisions.
1,165,927 Fate Therapeutics, Inc. $FATE Shares Bought by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly increased its stake in Fate Therapeutics, Inc. (NASDAQ:FATE) by 799.5%, purchasing an additional 1,165,927 shares to bring its total to 1.31 million shares, valued at approximately $3.1 million. This move is part of broader institutional investment, with 97.54% of the stock now held by hedge funds and other institutional investors. Despite mixed analyst ratings, Fate Therapeutics maintains a "Hold" consensus with an average price target of $5.90, as the clinical-stage biopharmaceutical company reported a quarterly loss but met revenue expectations.
Fate Therapeutics reports USD 2.08 million revenue for stock investors
Fate Therapeutics reported second-quarter 2026 revenue of USD 2.08 million, exceeding the USD 2.05 million consensus. Despite this, the company posted an adjusted loss per share of minus USD 0.25, matching analyst expectations. The stock was trading at EUR 1.85 at Lang & Schwarz on October 20, 2026, with a market capitalization of USD 243.6 million, highlighting the company's focus on development and funding discipline within the biotechnology sector.
Fate Therapeutics stock stands 97.96 percent higher year to date
Fate Therapeutics stock has seen a significant year-to-date increase of 97.96% despite a recent daily decline. The company reported second-quarter revenue of USD 2.08 million, exceeding analyst expectations, but also a net loss of USD 30.2 million. The stock trades within a 52-week range of USD 0.95 to USD 3.23 and currently has a market capitalization of USD 223.6 million.
Fate Therapeutics appoints Jamie Harrell to lead commercialization
Fate Therapeutics (NASDAQ:FATE) has appointed Jamie Harrell to its executive leadership team to lead commercial and market development strategy for its autoimmunity and oncology programs. Harrell brings over 25 years of commercial leadership experience and will oversee strategies for key drug candidates like FT819 and FT839, as well as physician engagement for the company's off-the-shelf CAR T-cell programs. He previously held senior commercial roles at Aurinia Pharmaceuticals, Avalo Therapeutics, and Covidien, contributing to the commercialization of over 25 products.
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy
Fate Therapeutics Inc. (NASDAQ:FATE) has appointed Jamie Harrell to its executive leadership team to lead the commercial and market development strategy for its autoimmunity and oncology programs. Harrell brings over 25 years of commercial leadership experience, including his most recent role at Aurinia Pharmaceuticals, where he worked on an oral therapy for lupus nephritis. He will be responsible for the commercial strategy of FT819 and FT839, and for developing physician engagement strategies for the company’s off-the-shelf CAR T-cell programs.
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy By Investing.com
Fate Therapeutics (NASDAQ:FATE) has appointed Jamie Harrell to its executive leadership team to lead the commercial and market development strategy for its autoimmunity and oncology programs. Harrell brings over 25 years of commercial leadership experience, having previously worked at Aurinia Pharmaceuticals, Avalo Therapeutics, and Covidien, and has contributed to the commercialization of more than 25 products. His role will include overseeing commercial strategy for clinical trials like FT819 and FT839, and developing physician engagement strategies for the company's CAR T-cell programs.
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com
Fate Therapeutics (NASDAQ:FATE) has appointed Jamie Harrell to its executive leadership team to lead commercial and market development strategy for its autoimmunity and oncology programs. Harrell brings over 25 years of experience in pharmaceutical commercialization, having previously worked at Aurinia Pharmaceuticals, Avalo Therapeutics, and Covidien. He will oversee the commercial strategy for key trials and physician engagement for the company's CAR T-cell programs.
Fate Therapeutics appoints Jamie Harrell to lead commercialization of CAR T-cell therapies for autoimmune diseases.
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to lead the commercialization of its CAR T-cell therapies, including FT819 and FT839, for autoimmune diseases. Harrell's role will focus on expanding patient access to these off-the-shelf cellular immunotherapies from clinical trials to market, particularly in community healthcare settings. This strategic hire aims to transform autoimmune disease treatment with Fate's innovative therapies.
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com
Fate Therapeutics (NASDAQ:FATE) has appointed Jamie Harrell to its executive leadership team to spearhead commercial and market development strategies for its autoimmunity and oncology programs. Harrell brings over 25 years of pharmaceutical commercialization experience, having previously worked at Aurinia Pharmaceuticals, Avalo Therapeutics, and Covidien. His role will include overseeing commercial strategy for key clinical programs like FT819 and FT839, and developing physician engagement for the company's off-the-shelf CAR T-cell programs.
Fate Therapeutics names Jamie Harrell SVP of commercial operations
Fate Therapeutics (NASDAQ: FATE) has appointed Jamie Harrell as Senior Vice President of Market Development and Commercial Operations, effective October 12, 2026. Harrell will be responsible for leading the company's commercial and market development strategies for its autoimmunity and oncology programs. He brings over 25 years of commercial experience, including leadership roles at Aurinia Pharmaceuticals, Avalo Therapeutics, and Covidien, and a strong background in the autoimmune landscape.
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics.
Fate Therapeutics (FATE) has appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, effective October 12, 2026. Harrell, who has over 25 years of commercial leadership experience and has contributed to the commercialization of three blockbuster therapies, will lead the commercial and market development strategy for the company's autoimmune disease and oncology programs. His expertise will be crucial as Fate Therapeutics advances its CAR T-cell therapies, such as FT819 and FT839, towards commercialization, particularly focusing on outpatient administration for broader patient access.
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations. He will lead the commercialization of the company's CAR T-cell therapies, including FT819 for lupus nephritis and FT839 for other autoimmune diseases. Harrell brings over 25 years of commercial leadership experience, particularly in launching first-in-class therapies and building commercial organizations in autoimmune disease.
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations. He will lead the commercialization efforts for the company's CAR T-cell therapies, particularly focusing on autoimmune diseases like lupus nephritis. Harrell brings over 25 years of commercial leadership experience, including launching first-in-class therapies and developing strategies for outpatient administration of CAR T-cell treatments.